Printer Friendly

MEDICAL GRAPHICS SELLS SYSTEMS TO NASA FOR SPACE PHYSIOLOGIC STUDIES

 ST. PAUL, Minn., Nov. 8 /PRNewswire/ -- Medical Graphics Corporation (NASDAQ: MGCC) announced today that it has finalized a contract with NASA to provide multiple MedGraphics Cardiopulmonary Exercise (CPX/D) Testing Systems to measure astronauts' cardiopulmonary response to exercise during space missions.
 The project reflects NASA's shift into the health sciences and its emphasis on collecting data that will have a global impact on preventive health care. The MedGraphics systems will be used during the orbiting phase of space shuttle flights to measure the effects of space travel, such as physical inactivity and weightlessness, on the astronauts' physical functions. Physical inactivity is a leading risk factor for cardiovascular disease, the primary cause of death and rising health care costs.
 NASA chose MedGraphics systems because they were the only ones that met the agency's stringent accuracy requirements. The system's preVent disposable pneumotach (a mouthpiece which measures the air flow and volume of a person's breath) has a proven accuracy capability of plus or minus one percent, while other devices attain an accuracy level of only five to eight percent.
 MedGraphics systems, such as the CPX/D, measure oxygen uptake -- called peak VO2 or VO2max -- which is the maximum amount of oxygen an individual consumes during exercise. The systems also measure a person's anaerobic threshold, a measurement used to determine an individual's optimal training zone. These measurements are regarded by leading physicians and scientists as the best indicators of physical fitness and global cardiovascular function.
 "NASA's selection of MedGraphics systems for this important scientific program is an indication of the widespread acceptance of VO2 monitoring as a key indicator of an individual's overall physical function and health," said Catherine A. Anderson, Medical Graphics Corporation's chairman, president and chief executive officer. "We're finding that an increasing number of physicians are using tests such as those performed on our CPX/D systems as part of an evaluation to determine a patient's cardiac and pulmonary health and for developing exercise prescriptions or appropriate therapy."
 The total value of the contract is $370,000. Medical Graphics Corporation was authorized to begin work on the contract in July. Contract revenues are divided evenly between the third and fourth quarters of the company's current fiscal year.
 Medical Graphics Corporation designs, manufactures and markets non- invasive diagnostic systems for the prevention, early diagnosis and cost-effective treatment of heart and lung disease. The Company's products are sold worldwide to hospitals, clinics, physician offices, sports medicine clinics, and to corporations for their wellness programs.
 -0- 11/8/93
 /CONTACT: Catherine A. Anderson, chairman, president & CEO, or Russ Acorn, vice president, R&D, of Medical Graphics, 612-484-4874/
 (MGCC)


CO: Medical Graphics Corporation ST: Minnesota IN: MTC SU:

DS -- MN004 -- 1673 11/08/93 10:17 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 8, 1993
Words:453
Previous Article:THE NWNL COMPANIES ESTABLISHES NORTHSTAR INVESTMENT MANAGEMENT CORPORATION TO MANAGE AND DISTRIBUTE THE NWNL NORTHSTAR SERIES TRUST
Next Article:SCIMED TO DISPLAY PRODUCTS AT AMERICAN HEART ASSOCIATION'S 66TH SCIENTIFIC SESSIONS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters